SCHEMBL1241602

SCHEMBL1241602

CCCOc1ccc(N(Cc2ccc(C(C)(C)C)cc2)C(=O)C(=O)OC)cc1-c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.43

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 9/20 0.43
GCGR P47871 2/20 0.43
GIPR P48546 2/20 0.43
GLP1R P43220 1/20 0.43
NR1H4 Q96RI1 4/20 0.41
EPHX2 P34913 1/20 0.41
LTB4R2 Q9NPC1 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
NR1I2 O75469 1/20 0.36
TRPV1 Q8NER1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1241719 0.97 SERPINE1 (0.43) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1239734 0.92 SERPINE1 (0.54) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1239963 0.91 SERPINE1 (0.55) SERPINE1NR1H4LTB4R2
SCHEMBL15434072 0.90 SERPINE1 (0.46) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1241711 0.89 SERPINE1 (0.51) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1239824 0.88 SERPINE1 (0.54) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1242450 0.88 SERPINE1 (0.43) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1242541 0.87 SERPINE1 (0.44) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1242896 0.86 NR1H4 (0.42) SERPINE1GCGRGIPRGLP1RNR1H4
SCHEMBL1242314 0.86 SERPINE1 (0.48) SERPINE1GCGRGIPRGLP1RNR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633245-B2 PAI-1 inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2014-01-21 US disclosed
US-7884234-B2 N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-02-08 US disclosed
US-7884234-B2 N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-02-08 US disclosed
US-20090312315-A1 PAI-1 INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-17 US disclosed
US-20090215899-A9 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-08-27 US disclosed
US-20090215899-A9 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-08-27 US disclosed
EP-2072498-A1 N-PHENYLOXAMIDIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-06-24 EP disclosed
US-20080249175-A1 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-10-09 US disclosed
US-20080249175-A1 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249175-A1 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 SERPINE1 1/4885GCGR 1724/4885GIPR 2082/4885
US-20090215899-A9 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 SERPINE1 1/4885GCGR 1724/4885GIPR 2082/4885
US-20090312315-A1 PAI-1 INHIBITOR SERPINC1, SERPINE1, SERPINH1 SERPINE1 2/4885GCGR 733/4885GIPR 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.